New Cell-Free Therapy for Cancer
Designer extracellular vesicles for cancer therapy
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11134704
This project is developing a new cell-free treatment using tiny packages from immune cells to fight solid cancers like melanoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11134704 on ClinicalTrials.gov |
What this research studies
We are creating special tiny packages, called extracellular vesicles (EVs), from engineered immune cells to deliver powerful cancer-fighting agents directly to tumors. These designer EVs are intended to overcome common challenges with existing CAR-T cell therapies, such as difficulty reaching solid tumors, losing effectiveness, and causing severe side effects. Our approach focuses on targeting a specific protein, DR5, which is found on cancer cells and other cells that help tumors grow. We have seen promising results in laboratory models, where these EVs effectively killed melanoma cells and slowed tumor growth.
Who could benefit from this research
Good fit: Patients with solid cancers, such as melanoma, who might benefit from new immunotherapy approaches could be ideal candidates for future clinical applications of this research.
Not a fit: Patients with cancers that do not express the DR5 protein or those whose cancer is not a solid tumor may not benefit from this specific therapy.
Why it matters
Potential benefit: If successful, this new therapy could offer a safer and more effective way to treat solid cancers, especially those that don't respond well to current CAR-T cell treatments.
How similar studies have performed: This approach is novel, building on preclinical discoveries that show promising results in laboratory cancer models, suggesting a new direction for cancer immunotherapy.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XU, XIAOWEI — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: XU, XIAOWEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.